Colistin dry powder inhalation - PureIMS
Alternative Names: Colistimethate sodium dry powder inhalation - PureIMS; Colistin CyclopsTMLatest Information Update: 28 Oct 2023
At a glance
- Originator PureIMS
- Class Antibacterials; Peptide antibiotics; Polymixins
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bronchiectasis; Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Bronchiectasis in Netherlands (Inhalation, Powder)
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Cystic-fibrosis-associated-respiratory-tract-infections in Netherlands (Inhalation, Powder)
- 30 Aug 2021 PureIMS has patent protection for CyclopsTM